Dividendos de Iconovo

Dividendo controles de criterios 0/6

Iconovo no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	1.5%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-SEK 2.45
Previsión de rentabilidad por dividendo	18.8%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Iconovo AB (publ)'s (STO:ICO) Intrinsic Value Is Potentially 37% Above Its Share Price

Jun 13

Companies Like Iconovo (STO:ICO) Can Afford To Invest In Growth

Apr 13

When Will Iconovo AB (publ) (STO:ICO) Turn A Profit?

Mar 18

Have Iconovo AB (publ) (STO:ICO) Insiders Been Selling Their Stock?

Feb 20

A Look At Iconovo's (STO:ICO) Share Price Returns

Feb 07

Have Insiders Been Buying Iconovo AB (publ) (STO:ICO) Shares?

Dec 21

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de ICO han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de ICO han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Iconovo vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de ICO con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (ICO)	n/a
Suelo de mercado 25% (SE)	1.5%
Techo de mercado 25% (SE)	4.3%
Media de la industria (Medical Equipment)	1.5%
Analista de previsiones (ICO) (hasta 3 años)	18.8%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de ICO en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de ICO en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de ICO para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que ICO no ha comunicado ningún pago.

Dividendos de Iconovo

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

New minor risk - Share price stability

Price target increased by 12% to kr23.50

New major risk - Market cap size

Should You Investigate Iconovo AB (publ) (STO:ICO) At kr6.68?

Now 21% undervalued after recent price drop

Consensus revenue estimates increase by 17%

Iconovo AB (publ) Develops Intranasally Inhaled Semaglutide in ICOone Nasal for More User-Friendly Treatment of Overweight and Obesity

Vice President of Operations recently bought kr57k worth of stock

Second quarter 2024 earnings released: kr0.60 loss per share (vs kr1.32 loss in 2Q 2023)

Now 21% overvalued after recent price rise

Iconovo AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vice President of Operations recently bought kr80k worth of stock

Independent Director recently bought kr246k worth of stock

Now 22% overvalued after recent price rise

Iconovo AB (Publ) Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments

Consensus revenue estimates increase by 15%, EPS downgraded

New major risk - Shareholder dilution

Iconovo AB (publ) Receives Patent Protection for Icores in China

Iconovo AB (publ), Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: kr0.69 loss per share (vs kr1.35 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Iconovo AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 18.8 million.

Iconovo AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

New major risk - Market cap size

Insufficient new directors

New minor risk - Profitability

New major risk - Market cap size

Independent Chairman of the Board recently bought kr190k worth of stock

Third quarter 2023 earnings released: kr0.97 loss per share (vs kr1.14 loss in 3Q 2022)

Iconovo AB (publ) Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone

Iconovo AB (publ) Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations

Iconovo AB (Publ) Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027

New minor risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings released: kr1.36 loss per share (vs kr1.38 loss in 2Q 2022)

We're A Little Worried About Iconovo's (STO:ICO) Cash Burn Rate

Price target decreased by 27% to kr63.00

Iconovo AB (publ) Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment

Iconovo AB (Publ) Announces Appoints Carl Lindgren as Chief Business Development Officer

Independent Director recently sold kr98k worth of stock

Independent Director recently sold kr171k worth of stock

Chief Executive Officer recently bought kr61k worth of stock

Independent Chairman of the Board recently bought kr100k worth of stock

Iconovo AB (publ) to Report Fiscal Year 2022 Results on Feb 08, 2023

Insufficient new directors

Iconovo Receives Approval of New European Patent for Its Single-Use Inhaler ICOone®

Iconovo AB (publ) Announces Executive Changes, Effective April 1, 2023

Iconovo's ICOone Inhaler Platform Receives New Patent Approval in the US

Iconovo Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr1.14 loss per share (vs kr0.43 loss in 3Q 2021)

Iconovo AB (publ) Conducts a User Study to Assess the Handling of its ICOone Nasal Inhaler

Here's Why We're Watching Iconovo's (STO:ICO) Cash Burn Situation

Second quarter 2022 earnings released: kr1.38 loss per share (vs kr0.85 loss in 2Q 2021)

Iconovo AB (Publ) Announces First Patent Grant in Japan for It's ICOone

Chief Executive Officer recently bought kr69k worth of stock

Director recently bought kr258k worth of stock

Chief Executive Officer recently bought kr104k worth of stock

Price target increased to kr140

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Iconovo AB (publ) Announces Completion of Comparative Clinical Study of Icores Budesonide/Formoterol and Symbicort Turbuhaler

Chief Financial Officer recently bought kr53k worth of stock

Director recently bought kr78k worth of stock

No longer forecast to breakeven

Director recently bought kr109k worth of stock

Chairman of the Board recently bought kr372k worth of stock

Companies Like Iconovo (STO:ICO) Are In A Position To Invest In Growth

Chief Executive Officer recently bought kr151k worth of stock

Third quarter 2021 earnings released

Chairman of the Board recently bought kr248k worth of stock

Insider recently bought kr53k worth of stock

Chairman of the Board recently bought kr421k worth of stock

We're Not Worried About Iconovo's (STO:ICO) Cash Burn

Is Now The Time To Look At Buying Iconovo AB (publ) (STO:ICO)?

Chairman of the Board recently bought kr378k worth of stock